静注人免疫球蛋白辅助治疗系统性红斑狼疮的可行性分析

Feasibility Analysis of Intravenous Human Immunoglobulin in the Treatment of Systemic Lupus Erythematosus

目的:探讨人免疫球蛋白在辅助治疗系统性红斑狼疮的临床效果。方法:按照入选标准,选取本院2014年1月-2016年2月收治的系统性红斑狼疮患者82例,按照随机数字表法将其分为观察组和对照组,各41例。对照组给予吗替麦考酚酯胶囊治疗,观察组在对照组基础上给予人免疫球蛋白静注治疗。6个月后观察两组患者临床疗效、系统性红斑狼疮疾病活动指数(SLEDAI)、24 h尿蛋白、补体C3/C4变化的差异,采用SLE-Qo L量表评价患者生活质量,观察两组不良反应发生率。结果:6个月后,观察组临床疗效显著高于对照组(92.68%vs 78.05%),差异有统计学意义(P<0.05)。观察组患者SLEDAI、SLE-QoL量表评分均显著优于对照组(P<0.05)。两组患者24 h尿蛋白定量、补体C3/C4水平明显优于治疗前,且观察组与对照组比较指标改善更明显,差异均有统计学意义(P<0.05)。不良反应发生率方面,观察组与对照组比较(17.07%vs 41.46%),差异有统计学意义(P<0.05)。结论:系统性红斑狼疮在应用吗替麦考酚酯基础上辅以人免疫球蛋白静注治疗,临床效果显著,各项化验指标下降明显,不良反应少,患者生活质量好,值得临床推广。

Objective： To investigate the clinical effect of human immunoglobulin in the treatment of Systemic Lupus Erythematosus.Method： According to the criteria, 82 patients with systemic lupus erythematosus treated in our hospital from January 2014 to February 2016 were randomly divided into observation group and control group according to the random number table method. The control group was given mycophenolate mofetil capsules, oral.The observation group was intravenous injection Human Immunoglobulin and on the basis of the control group. SLEDAI, 24h urinary protein and complement C3/C4 were observed after 6 months,The quality of life of patients was evaluated by SLE-QoL scale.The incidence of adverse reactions of two groups were observed.Result： After 6 months, the clinical curative effect of the observation group was significantly higher than the control （ 92.68% vs 78.05% ）, there was statistical significance （ P〈0.05 ） .SLEDAI and SLE-QoL scores were significantly （ P〈0.05 ） . The levels of urinary protein and complement C3/C4 in two groups were significantly better than those before treatment, and the difference between the observation group and the controi group was significant （ P〈0.05 ） . There was a significant difference between the observation group and the control group （ 17.07% vs 41.46% ）, there was statistical significance （P〈0.05） .Conclusion： Systemic lupus erythematosus is a kind of human immunoglobulin intravenous therapy on the basis of mycophenolate mofetil. The clinical effect is obvious, the test indexes are decreased obviously, the adverse reaction is small, the quality of life is goodand worthy of clinical promotion.